Tag: IND application
Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.
The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a…
To treat patients with solid tumours, Sensei Biotherapeutics has submitted an IND application to the US FDA for a phase 1/2 trial of SNS-101.
An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the…
